Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

P. Murali Doraiswamy, R. A. Sperling, K. Johnson, Eric M. Reiman, T. Z. Wong, M. N. Sabbagh, Carl H. Sadowsky, A. S. Fleisher, A. Carpenter, A. D. Joshi, M. Lu, M. Grundman, M. A. Mintun, D. M. Skovronsky, M. J. Pontecorvo, Ranjan Duara, Marwan Sabbagh, Geoffrey Lawrence Ahern, Richard F. Holub, Mildred V. FarmerBeth Emmie Safirstein, Gustavo Alva, Crystal F. Longmire, George Jewell, Keith A. Johnson, Ron Korn, Jeanette K. Wendt, Dean Wong, R. Edward Coleman, Michael Devous, Danna Jennings, Michael W. Weiner, Cynthia A. Murphy, Karel D. Kovnat, Jeff D. Williamson

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

Original languageEnglish (US)
Pages (from-to)1044-1051
Number of pages8
JournalMolecular Psychiatry
Volume19
Issue number9
DOIs
StatePublished - Sep 11 2014
Externally publishedYes

Fingerprint

Amyloid
Multicenter Studies
Prospective Studies
Electrons
Alzheimer Disease
Pathology
Cognition
Cognitive Dysfunction
florbetapir

Keywords

  • alzheimer's disease
  • amyloid
  • cognitive decline
  • florbetapir
  • MCI
  • PET

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., ... Williamson, J. D. (2014). Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry, 19(9), 1044-1051. https://doi.org/10.1038/mp.2014.9

Florbetapir F 18 amyloid PET and 36-month cognitive decline : a prospective multicenter study. / Doraiswamy, P. Murali; Sperling, R. A.; Johnson, K.; Reiman, Eric M.; Wong, T. Z.; Sabbagh, M. N.; Sadowsky, Carl H.; Fleisher, A. S.; Carpenter, A.; Joshi, A. D.; Lu, M.; Grundman, M.; Mintun, M. A.; Skovronsky, D. M.; Pontecorvo, M. J.; Duara, Ranjan; Sabbagh, Marwan; Ahern, Geoffrey Lawrence; Holub, Richard F.; Farmer, Mildred V.; Safirstein, Beth Emmie; Alva, Gustavo; Longmire, Crystal F.; Jewell, George; Johnson, Keith A.; Korn, Ron; Wendt, Jeanette K.; Wong, Dean; Coleman, R. Edward; Devous, Michael; Jennings, Danna; Weiner, Michael W.; Murphy, Cynthia A.; Kovnat, Karel D.; Williamson, Jeff D.

In: Molecular Psychiatry, Vol. 19, No. 9, 11.09.2014, p. 1044-1051.

Research output: Contribution to journalArticle

Doraiswamy, PM, Sperling, RA, Johnson, K, Reiman, EM, Wong, TZ, Sabbagh, MN, Sadowsky, CH, Fleisher, AS, Carpenter, A, Joshi, AD, Lu, M, Grundman, M, Mintun, MA, Skovronsky, DM, Pontecorvo, MJ, Duara, R, Sabbagh, M, Ahern, GL, Holub, RF, Farmer, MV, Safirstein, BE, Alva, G, Longmire, CF, Jewell, G, Johnson, KA, Korn, R, Wendt, JK, Wong, D, Coleman, RE, Devous, M, Jennings, D, Weiner, MW, Murphy, CA, Kovnat, KD & Williamson, JD 2014, 'Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study', Molecular Psychiatry, vol. 19, no. 9, pp. 1044-1051. https://doi.org/10.1038/mp.2014.9
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry. 2014 Sep 11;19(9):1044-1051. https://doi.org/10.1038/mp.2014.9
Doraiswamy, P. Murali ; Sperling, R. A. ; Johnson, K. ; Reiman, Eric M. ; Wong, T. Z. ; Sabbagh, M. N. ; Sadowsky, Carl H. ; Fleisher, A. S. ; Carpenter, A. ; Joshi, A. D. ; Lu, M. ; Grundman, M. ; Mintun, M. A. ; Skovronsky, D. M. ; Pontecorvo, M. J. ; Duara, Ranjan ; Sabbagh, Marwan ; Ahern, Geoffrey Lawrence ; Holub, Richard F. ; Farmer, Mildred V. ; Safirstein, Beth Emmie ; Alva, Gustavo ; Longmire, Crystal F. ; Jewell, George ; Johnson, Keith A. ; Korn, Ron ; Wendt, Jeanette K. ; Wong, Dean ; Coleman, R. Edward ; Devous, Michael ; Jennings, Danna ; Weiner, Michael W. ; Murphy, Cynthia A. ; Kovnat, Karel D. ; Williamson, Jeff D. / Florbetapir F 18 amyloid PET and 36-month cognitive decline : a prospective multicenter study. In: Molecular Psychiatry. 2014 ; Vol. 19, No. 9. pp. 1044-1051.
@article{99f0f20dbc494380a0c307b9a8895665,
title = "Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study",
abstract = "This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37{\%} (19/52) of MCI and 68{\%} (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P",
keywords = "alzheimer's disease, amyloid, cognitive decline, florbetapir, MCI, PET",
author = "Doraiswamy, {P. Murali} and Sperling, {R. A.} and K. Johnson and Reiman, {Eric M.} and Wong, {T. Z.} and Sabbagh, {M. N.} and Sadowsky, {Carl H.} and Fleisher, {A. S.} and A. Carpenter and Joshi, {A. D.} and M. Lu and M. Grundman and Mintun, {M. A.} and Skovronsky, {D. M.} and Pontecorvo, {M. J.} and Ranjan Duara and Marwan Sabbagh and Ahern, {Geoffrey Lawrence} and Holub, {Richard F.} and Farmer, {Mildred V.} and Safirstein, {Beth Emmie} and Gustavo Alva and Longmire, {Crystal F.} and George Jewell and Johnson, {Keith A.} and Ron Korn and Wendt, {Jeanette K.} and Dean Wong and Coleman, {R. Edward} and Michael Devous and Danna Jennings and Weiner, {Michael W.} and Murphy, {Cynthia A.} and Kovnat, {Karel D.} and Williamson, {Jeff D.}",
year = "2014",
month = "9",
day = "11",
doi = "10.1038/mp.2014.9",
language = "English (US)",
volume = "19",
pages = "1044--1051",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Florbetapir F 18 amyloid PET and 36-month cognitive decline

T2 - a prospective multicenter study

AU - Doraiswamy, P. Murali

AU - Sperling, R. A.

AU - Johnson, K.

AU - Reiman, Eric M.

AU - Wong, T. Z.

AU - Sabbagh, M. N.

AU - Sadowsky, Carl H.

AU - Fleisher, A. S.

AU - Carpenter, A.

AU - Joshi, A. D.

AU - Lu, M.

AU - Grundman, M.

AU - Mintun, M. A.

AU - Skovronsky, D. M.

AU - Pontecorvo, M. J.

AU - Duara, Ranjan

AU - Sabbagh, Marwan

AU - Ahern, Geoffrey Lawrence

AU - Holub, Richard F.

AU - Farmer, Mildred V.

AU - Safirstein, Beth Emmie

AU - Alva, Gustavo

AU - Longmire, Crystal F.

AU - Jewell, George

AU - Johnson, Keith A.

AU - Korn, Ron

AU - Wendt, Jeanette K.

AU - Wong, Dean

AU - Coleman, R. Edward

AU - Devous, Michael

AU - Jennings, Danna

AU - Weiner, Michael W.

AU - Murphy, Cynthia A.

AU - Kovnat, Karel D.

AU - Williamson, Jeff D.

PY - 2014/9/11

Y1 - 2014/9/11

N2 - This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

AB - This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

KW - alzheimer's disease

KW - amyloid

KW - cognitive decline

KW - florbetapir

KW - MCI

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84905557091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905557091&partnerID=8YFLogxK

U2 - 10.1038/mp.2014.9

DO - 10.1038/mp.2014.9

M3 - Article

C2 - 24614494

AN - SCOPUS:84905557091

VL - 19

SP - 1044

EP - 1051

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 9

ER -